Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and Cara Therapeutics (NASDAQ: CARA)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (NASDAQ: REGN) and Cara Therapeutics (NASDAQ: CARA) with bullish sentiments.

Regeneron (NASDAQ: REGN)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Regeneron (NASDAQ: REGN), with a price target of $522. The company’s shares opened today at $445.68.

According to TipRanks.com, Newman is a 4-star analyst with an average return of 4.4% and a 42.9% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $500.20, representing a 12.2% upside.

In a report issued on October 5, Piper Jaffray also maintained a Buy rating on the stock.
Cara Therapeutics (NASDAQ: CARA)

In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (NASDAQ: CARA), with a price target of $23. The company’s shares opened today at $12.87.

Carr wrote:

“Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 8.7% and a 45.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Cara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.